Diagnosis

Hepatic encephalopathy

Altered mental status due to accumulation of neurotoxic substances (ammonia, GABA) in the bloodstream.

Also known as: Portal systemic encephalopathy

Etiology

Cause (World Health Congress of Gastroenterology Criteria) [ura]

Precipitating factors [ura]

Pathophysiology [ura]

  1. Colonic bacteria and mucosal enzymes break down dietary proteins --> releasing ammonia in the GI tract

  2. Ammonia is absorbed into the portal circulation --> converted into urea in the liver.

  3. Liver failure or systemic shunting --> ammonia accumulate in the systemic circulation

  4. Hyperammonemia --> astrocyte swelling/dysfunction

    • Astrocytes maintain electrolyte homeostasis, provide nutrients and neurotransmitter precursors to neurons

  5. Hyperammonemia --> impair neurotransmission --> hepatic encephalopathy:

    • Early phase: disrupted sleep-wake pattern (sleep during daytime, awake at night)

    • Intermediate stage: confusion, lethargy, and personality changes

    • Advanced stage: coma

Complications [ura]

Epidemiology

Incidence per 100.000 [mc4][rtu][utr][mzf][gee][w32]

Epidemiology chart for Incidence

Symptoms & findings

Symptoms

Asterixis, Coma, Decreased consciousness, Edema, Hematochezia, Lethargy, Pruritus, Spider nevus

Clinical findings

Ascites, Decreased Albumin, Elevated Ammonia, Elevated Bilirubin, Elevated Estrogen, Elevated PT-INR, Jaundice, Palmar erythema

Anamneses

None listed.

Localized findings

Swelling
Radiates
Abdomen
Onset
Gradual (days)
Pattern
Constant

Approach

West Haven Criteria [ura]

Treatment

The goals of treatment: [n7s]

The treatment and management of HE depend on its severity and acuity: [ksd]

  1. Acute episode:

    • Lactulose (non-absorbable disaccharide) is first-line therapy (self-titrate to achieve 2 to 4 soft bowel movements daily)

    • Rifaximin (non-absorbable oral antibiotic)

    • L-ornithine L-aspartate i.v. (oral branched-chain amino acids)

    • Ornithine Phenylacetate

    • Glycerol Phenylbutyrate

    • Correct zinc deficiency (low levels of zinc lead to impairment of urea cycle enzymes and glutamine synthetase, thus leading to increased ammonia levels)

    • Albumin Dialysis

    • Alternative treatment: neomycin, metronidazole (ototoxicity, nephrotoxicity, and antibiotic resistance)

  2. Prophylaxis: [ura]

    • Lactulose

    • Rifaximin

    • Probiotics

    • Nutrition: many small meals to prevent fasting (may increase ammonia)

      • Energy: 35 to 40 kcal/kg/d

      • Protein: 1.2 to 1.5 g/kg/d

  3. Liver transplantation is the definitive surgery

Differential diagnoses

Alcohol intoxication, Brain abscess, Brain tumor, Drug side effects, Encephalitis, Hypercalcemia, Hypercarbia, Hyperkalemia, Hypernatremia, Hypocalcemia, Hypoglycemia, Hypokalemia, Hyponatremia, Hypoxemia, Inherited urea cycle disorder, Intracerebral hemorrhage, Meningitis, Postseizure encephalopathy, Renal failure, Stroke, Subdural hematoma, Ureterosigmoidostomy, Wernicke encephalopathy


References

[1] Mandiga P, Kommu S, Bollu PC. Hepatic Encephalopathy. [Updated 2025 Jan 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430869/

[2] Maldonado-Garza HJ, Vázquez-Elizondo G, Gaytán-Torres JO, Flores-Rendón AR, Cárdenas-Sandoval MG, Bosques-Padilla FJ. Prevalence of minimal hepatic encephalopathy in cirrhotic patients. Ann Hepatol. 2011 Jun;10 Suppl 2:S40-4.

[3] Liu YB, Chen MK. Epidemiology of liver cirrhosis and associated complications: Current knowledge and future directions. World J Gastroenterol. 2022 Nov 7;28(41):5910-5930.

[4] Louissaint J, Deutsch-Link S, Tapper EB. Changing Epidemiology of Cirrhosis and Hepatic Encephalopathy. Clin Gastroenterol Hepatol. 2022 Aug;20(8S):S1-S8.

[5] Stepanova M, Mishra A, Venkatesan C, Younossi ZM. In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clin Gastroenterol Hepatol. 2012 Sep;10(9):1034-41.e1.

[6] Cordoba J, Ventura-Cots M, Simón-Talero M, Amorós À, Pavesi M, Vilstrup H, Angeli P, Domenicali M, Ginés P, Bernardi M, Arroyo V; CANONIC Study Investigators of EASL-CLIF Consortium. Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). J Hepatol. 2014 Feb;60(2):275-81.

[7] Vaz J, Eriksson B, Strömberg U, Buchebner D, Midlöv P. Incidence, aetiology and related comorbidities of cirrhosis: a Swedish population-based cohort study. BMC Gastroenterol. 2020 Apr 3;20(1):84.

[8] Flamm SL. Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy. Am J Med Sci. 2018 Sep;356(3):296-303.

[9] Patidar KR, Bajaj JS. Covert and Overt Hepatic Encephalopathy: Diagnosis and Management. Clin Gastroenterol Hepatol. 2015 Nov;13(12):2048-61.

[10] http://emedicine.medscape.com/article/186101 (2014-01-02); [Medscape]

Scroll to top